Outlook Therapeutics is trading at $1.46 (5.3% up) as it rebounds from recent volatility and dilution concerns.
- Shares have been under pressure since a July 17 filing registered approximately 17.3 million existing shares for resale, creating a significant market overhang.
- Today’s upward movement appears to be a technical bounce amid a broadly positive market environment rather than a response to fresh company-specific news.